Sava's $36M Raise: A Game-Changer for Diabetes Care?

·
Listen to this article~3 min

Sava Technologies raises $36M Series B to scale its wearable glucose microsensor and partners with Ascensia to bring it to Europe. A game-changer for diabetes care?

Sava Technologies, a London-based HealthTech company, just announced a €32.08 million ($36 million) Series B round to scale up manufacturing and get its wearable biosensor ready for the market. The round was led by Ascensia, with participation from Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments, Pentland Ventures, and others. This brings Sava's total funding to €60.6 million ($68 million). But the big news? Sava is teaming up with Ascensia as its commercialization and distribution partner, starting in Europe. Ascensia, a subsidiary of PHC Holdings Corporation, is a global player in diabetes care, selling products in over 90 countries. ### What Makes Sava's Technology Stand Out? Sava was founded in 2019 by Imperial College London bioengineers Renato Circi and Rafaël Michali. After five years in stealth, they emerged in June 2024 with a next-generation glucose microsensor. Their wearable device measures molecules just beneath the skin—painlessly and continuously. While it starts with glucose, it's designed to track other biomarkers too, opening doors beyond diabetes. Here's the kicker: Sava's microsensors are about ten times shorter than the filament in traditional continuous glucose monitors (CGMs). That means less skin disruption while still reaching interstitial fluid. And because they were designed for high-volume manufacturing from the start, they're built to reach millions. Renato Circi, co-founder and Co-CEO of Sava, said, "For decades, continuous monitoring has been held back by the same legacy technology. This is about to change. We're thrilled to be partnering with Ascensia, a global powerhouse in the space, to deliver, as a first step, something radically better to millions of people with diabetes." ### What's Next for Sava? Sava is planning a pivotal clinical study this year and is targeting CE approval for non-adjunctive use. That means the device could be used to make insulin dosing decisions without routine fingerstick confirmation—a big deal for people with diabetes. If approved, Ascensia will lead the commercial launch in Europe. Peter Bodlund, CEO of Ascensia, commented, "Microsensor technology has the potential to transform the day-to-day monitoring experience for people with diabetes. By bringing together Sava's innovative technology with Ascensia's deep diabetes expertise, strong reputation, and commercial capabilities, we have an exciting opportunity to address important unmet needs in diabetes care." This partnership could be a game-changer. Sava's technology promises a less invasive, more convenient way to monitor glucose and potentially other biomarkers. With Ascensia's global reach, it could soon be available to millions. - **Funding total:** €60.6 million ($68 million) to date - **Key investors:** Ascensia, Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments, Pentland Ventures - **Technology:** Wearable biosensor with microsensors 10x shorter than traditional CGM filaments - **Next steps:** Pivotal clinical study, CE approval, commercial launch in Europe Sava's journey from stealth to a major player in diabetes care is one to watch. With this funding and partnership, they're poised to make a real impact. Keep an eye on this space.

📌 Worth Reading Next